You are here: Industry Insights > Amgen

News List

With biosims closing in, Amgen CEO Bradway scored 10% raise to $18.6M in 2018 fiercepharma
April 10, 2019
Amgen CEO Bob Bradway racked up a 2018 pay package of $18.6 million, his first big raise since 2015……
Amgen CEO scores 10% raise to $18.6 million in 2018 fiercepharma
April 10, 2019
Amgen CEO Bob Bradway racked up a 2018 pay package of $18.6 million,his first big raise since 2015, thanks to incentive
Novartis and Amgen dispute over migraine drug reaches court pharmaceutical-technology
April 09, 2019
Novartis and Amgen dispute over migraine drug reaches court
Amgen, GSK, Novartis, BI spots head to the #FierceMadness Final Four fiercepharma
April 02, 2019
It's down to the Final Four in the #FierceMadness 2019 ad campaign tournament.
Amgen taps comedian Jay Leno for 'cholesterol 911' awareness push fiercepharma
March 19, 2019
Comedian and former late night host Jay Leno isn’t laughing about his cholesterol numbers. But he is using humor to get the message across in an awareness campaign with Amgen that focuses on the dangers of high cholesterol.
Orchard Therapeutics Adds CTO Role contractpharma
March 19, 2019
Zheng will oversee process development, manufacturing, quality, facilities and engineering, supply chain, and CMC program management.
Jury upholds Amgen's patents on Repatha® (evolocumab) worldpharmanews
March 01, 2019
Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies.
Sanofi, Regeneron lose patent dispute with Amgen over cholesterol drug pharmaceutical-technology
February 27, 2019
US District Court for the District of Delaware has upheld Amgen’s patent on cholesterol drug Repatha, rejecting a challenge filed by Sanofi and Regeneron.
Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure worldpharmanews
February 22, 2019
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure)
Amgen hunts for deals of all sizes to combat forthcoming sales decline fiercepharma
January 30, 2019
A couple Big Pharma players have come out against megamergers in recent weeks. But Amgen isn’t one of them.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page